07/24/2026
“Did the FDA just approve BPC-157?” No. Here’s what actually happened. On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the 503A Bulks List, the list of ingredients compounding pharmacies are allowed to use. The committee also voted in favor of KPV, TB-500, and MOTS-c.
What that means: a recommendation, not an approval. The vote is non-binding. The FDA still has to issue a formal rule before anything changes, and the agency’s own scientists opposed inclusion, citing limited human evidence. What that means: a recommendation, not an approval. The vote is non-binding. The FDA still has to issue a formal rule before anything changes, and the agency’s own scientists opposed inclusion, citing limited human evidence.
So what is BPC-157? A peptide, a short chain of amino acids, studied for a possible role in gut lining repair, soft tissue and tendon recovery, and the inflammation response. Most of that research is early and largely preclinical, meaning animal studies that do not always hold up in humans.
Where Solas stands: we follow the law and the science, in that order. If regulation changes, we will offer these only through proper channels, prescribed and pharmacy-compounded. Until then, we would rather tell you the truth than sell you a trend.
CTA:
Questions about peptide therapy, or wondering what is actually available and legal right now? Book a free 15-minute call with Celeste. Link in bio, or solasclinic.com.
Celeste Cisneros, FNP-BC · Solas Health & Wellness · Westside El Paso, serving Las Cruces
503A CompoundingPharmacy TB500 MOTSc KPV RegenerativeMedicine FunctionalMedicine GutHealth EvidenceBasedMedicine NursePractitioner ElPasoTX ElPasoWellness WestsideElPaso LasCruces SolasHealthAndWellness have you ever used BPC-157
